AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1558774 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cotrimoxazole administration
Number of subjects: 77
Study 1558774 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cotrimoxazole administration (3 days a week)
Number of subjects: 77
Study 2951060 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 9
Study 2951060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31767581 — intervention group
Group type: EXPERIMENTAL
Intervention: SHIFT intervention (6-month program including a 6-hour education session, worksite champion support, and equipment provision such as a Fitbit and resistance bands/balls)
Number of subjects: 168
Study 31767581 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control arm
Number of subjects: 168
Study 29602225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral microbiota in children developing allergic disease (asthma)
Number of subjects: 80
Study 29602225 — intervention group
Group type: COMPARATOR
Intervention: Oral microbiota in healthy children
Number of subjects: 80
Study 29602225 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemella haemolysans in children developing allergies
Number of subjects: 80
Study 29602225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri and L. crispatus in healthy children
Number of subjects: 80
Study 26831541 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetyl-cysteine (NAC)
Number of subjects: 11
Study 26831541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24986943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm incision
Number of subjects: 60
Study 24986943 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cm incision
Number of subjects: 60
Study 24986943 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cm incision
Number of subjects: 60
Study 24986943 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study 22942167 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 151
Study 22942167 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 151
Study 19896336 — intervention group
Group type: EXPERIMENTAL
Intervention: Early behavioural intervention (EBI)
Number of subjects: 61
Study 19896336 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 61
Study 18694141 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated outcomes surveillance system (DELTA)
Number of subjects: 0
Study 18694141 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical Process Control (SPC) and Bayesian Updating Statistics (BUS) methodologies
Number of subjects: 0
Study 18694141 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 16298069 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable medication overuse headache (pMOH)
Number of subjects: 1861
Study 16298069 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pMOH
Number of subjects: 1861
Study 16298069 — intervention group
Group type: COMPARATOR
Intervention: Patients without pMOH
Number of subjects: 1861
Study 11964279 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg alternate-day oral prednisone
Number of subjects: 125
Study 11964279 — intervention group
Group type: COMPARATOR
Intervention: 10 mg alternate-day oral prednisone
Number of subjects: 125
Study 9856375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (NPA) 10 or 20 mg twice a day
Number of subjects: 63
Study 9856375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (NGITS) 30 or 60 mg once a day
Number of subjects: 63
Study 9856375 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 or 10 mg once a day
Number of subjects: 63
Study 9856375 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 63
Study 7654468 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and 1000 mg of supplemental calcium each day
Number of subjects: 0
Study 7654468 — intervention group
Group type: COMPARATOR
Intervention: Estrogen alone
Number of subjects: 0
Study 2762589 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (1 x 8 mg) and dixyrazine (4 x 10 mg)
Number of subjects: 100
Study 2762589 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide (4 x 1 mg/kg)
Number of subjects: 100
Study 2762589 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine
Number of subjects: 100
Study 2762589 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide
Number of subjects: 100
Study 2762589 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-dixyrazine and high-dose metoclopramide
Number of subjects: 100
Study 976301 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (beta-adrenergic receptor stimulatory agent)
Number of subjects: 0
Study 976301 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef meal
Number of subjects: 0
Study 976301 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol and beef meal combined
Number of subjects: 0
Study 976301 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic receptor blocking agent)
Number of subjects: 0
Study 976301 — intervention group
Group type: COMPARATOR
Intervention: Basal serum gastrin concentrations
Number of subjects: 0
Study 976301 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol and meal stimulated gastrin secretion
Number of subjects: 0
Study 31995619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab combination therapy
Number of subjects: 3
Study 31995619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 3
Study 31995619 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 3
Study 31037724 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tip tracking (NTT) for out-of-plane procedures
Number of subjects: 40
Study 31037724 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tip tracking (NTT)
Number of subjects: 40
Study 31037724 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tip tracking (NTT) for in-plane procedures
Number of subjects: 40
Study 31037724 — intervention group
Group type: COMPARATOR
Intervention: Control (without NTT) for in-plane procedures
Number of subjects: 40
Study 28282523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (A‐CRA)
Number of subjects: 1712
Study 26940721 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitated global budget and pay-for-performance (CGB + P4P)
Number of subjects: 0
Study 26940721 — intervention group
Group type: COMPARATOR
Intervention: Capitated global budget (CGB)
Number of subjects: 0
Study 26940721 — intervention group
Group type: COMPARATOR
Intervention: Both groups (CGB and CGB + P4P)
Number of subjects: 0
Study 25124565 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell therapy
Number of subjects: 943
Study 25124565 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 943
Study 21812536 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of CpG 7909 (1.05 mg/kg)
Number of subjects: 41
Study 21812536 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous dose of CpG 7909 (0.45 mg/kg)
Number of subjects: 41
Study 21812536 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple weekly subcutaneous doses of CpG 7909 (0.45 mg/kg)
Number of subjects: 41
Study 21812536 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG 7909 administration
Number of subjects: 41
Study 19294955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon, 8 mg nightly for 6 months
Number of subjects: 451
Study 19294955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 17465861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (needle-free injection)
Number of subjects: 107
Study 17465861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 107
Study 16083602 — intervention group
Group type: EXPERIMENTAL
Intervention: External vavuloplasty of the superficial femoral vein and surgery of superficial venous system (group A)
Number of subjects: 30
Study 16083602 — intervention group
Group type: COMPARATOR
Intervention: Surgery of superficial venous system only (group B)
Number of subjects: 30
Study 14727250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 126
Study 14727250 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and IMRT with subcutaneous amifostine (Ethyol, WR-2721)
Number of subjects: 126
Study 10225080 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte depleting arterial line filter (LG‐6 group)
Number of subjects: 40
Study 10225080 — intervention group
Group type: COMPARATOR
Intervention: Standard arterial line filter (AV‐6 group)
Number of subjects: 40
Study 8561317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg
Number of subjects: 90
Study 8561317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 90
Study 8561317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1901076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rtPA) 100 mg
Number of subjects: 67
Study 1901076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 6752448 — intervention group
Group type: COMPARATOR
Intervention: C 50+R 0.25
Number of subjects: 329
Study 6752448 — intervention group
Group type: COMPARATOR
Intervention: C 50+R 0.125
Number of subjects: 329
Study 6752448 — intervention group
Group type: COMPARATOR
Intervention: C 50+R 0.05
Number of subjects: 329
Study 6752448 — intervention group
Group type: COMPARATOR
Intervention: C 25+R 0.125
Number of subjects: 329
Study 31989690 — intervention group
Group type: EXPERIMENTAL
Intervention: basic vision rehabilitation service (basic-VRS)
Number of subjects: 0
Study 31989690 — intervention group
Group type: COMPARATOR
Intervention: usual low vision care
Number of subjects: 0
Study 31348731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of MenAC-TT vaccine
Number of subjects: 301
Study 31348731 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of MenAC-TT vaccine
Number of subjects: 301
Study 31348731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 1 and 2 doses of MenAC-TT vaccine
Number of subjects: 301
Study 28376919 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Number of subjects: 82
Study 28376919 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 82
Study 27137661 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Workshop (SW)
Number of subjects: 51
Study 27137661 — intervention group
Group type: COMPARATOR
Intervention: Online Curriculum (OC)
Number of subjects: 51
Study 24418178 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted orthognathic corrective surgery
Number of subjects: 20
Study 24418178 — intervention group
Group type: COMPARATOR
Intervention: Classic orthognathic corrective surgery
Number of subjects: 20
Study 22405221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 289
Study 22405221 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 289
Study 19190912 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase instillation (thrice daily)
Number of subjects: 100
Study 19190912 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation alone
Number of subjects: 100
Study 17552960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50 or 100 mg)
Number of subjects: 367
Study 17552960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10 or 20 mg)
Number of subjects: 367
Study 17552960 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil or Tadalafil
Number of subjects: 367
Study 16109114 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg/day) for 6 weeks
Number of subjects: 74
Study 16109114 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 74
Study 12454450 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory education group
Number of subjects: 102
Study 12454450 — intervention group
Group type: COMPARATOR
Intervention: Traditional education group
Number of subjects: 102
Study 9536583 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler devices (Accuhaler, Autohaler, Turbohaler, Diskhaler)
Number of subjects: 20
Study 9536583 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler and Accuhaler
Number of subjects: 20
Study 7971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 0
Study 7971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyoxyethylene 20 sorbitan monooleate (Tween)
Number of subjects: 0
Study 7971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetyltrimethylammonium bromide (CTAB)
Number of subjects: 0
Study 7971707 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of felodipine
Number of subjects: 0
Study 3661282 — intervention group
Group type: EXPERIMENTAL
Intervention: Impersonal recruitment (letters sent by employee mail)
Number of subjects: 119
Study 3661282 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal recruitment (personal phone calls)
Number of subjects: 119
Study 30697471 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives up to $320/year
Number of subjects: 2003
Study 30081574 — intervention group
Group type: EXPERIMENTAL
Intervention: Stringent group (S-group) with three meal replacements/day
Number of subjects: 321
Study 30081574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate group (M-group) with two meal replacements/day
Number of subjects: 321
Study 30081574 — intervention group
Group type: COMPARATOR
Intervention: Observational control group with routine care
Number of subjects: 321
Study 27042258 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation for four weeks
Number of subjects: 0
Study 27042258 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsupplemented group)
Number of subjects: 0
Study 25064674 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure visit-to-visit variability
Number of subjects: 2739
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC genotype
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC combined with IL12A rs568408 GG
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC combined with IL12A rs568408 GA
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC combined with IL12A rs568408 GG/AA
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: IL12B rs3212227 AA combined with IL18 rs360719 CC
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: rs568408 AA and rs360719 TT genotypes
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: rs568408 GG and rs360719 TT genotypes
Number of subjects: 518
Study 22863216 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3212227 CC and rs360719 TC genotypes
Number of subjects: 518
Study 19604407 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 13
Study 17805239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 15
Study 17805239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 14681845 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevioside (1 g)
Number of subjects: 12
Study 14681845 — intervention group
Group type: COMPARATOR
Intervention: Maize starch (1 g)
Number of subjects: 12
Study 11642632 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐HB‐IPV
Number of subjects: 400
Study 11642632 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐HB‐IPV at 2 and 4 months, DTaP‐HB with OPV at 6 months
Number of subjects: 400
Study 11642632 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP‐HB with licensed IPV (IPOL) administered separately
Number of subjects: 400
Study 11642632 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate doses of OPV, DTaP, and HB
Number of subjects: 400
Study 11642632 — intervention group
Group type: EXPERIMENTAL
Intervention: New IPV
Number of subjects: 400
Study 9494004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group (free fluids from 4 hours postoperatively, solid diet from first postoperative day as tolerated)
Number of subjects: 80
Study 9494004 — intervention group
Group type: COMPARATOR
Intervention: Control group (nil orally until passage of flatus or bowel motion, then fluids progressing to solids over 24-48 hours)
Number of subjects: 80
Study 9494004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 80
Study 8311205 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine infusion at 7 ml.h‐1 of a 0.25% solution
Number of subjects: 20
Study 8311205 — intervention group
Group type: COMPARATOR
Intervention: Epidural bupivacaine infusion at 25 ml.h‐1 of a 0.07% solution
Number of subjects: 20
Study 3230909 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval dance group
Number of subjects: 0
Study 3230909 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dance group
Number of subjects: 0
Study 3230909 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8252509 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin and flutamide
Number of subjects: 122
Study 8252509 — intervention group
Group type: COMPARATOR
Intervention: Buserelin alone
Number of subjects: 122
Study 343727 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (500-750 mg daily)
Number of subjects: 20
Study 343727 — intervention group
Group type: COMPARATOR
Intervention: phenylbutazone (400-600 mg daily)
Number of subjects: 20
Study 343727 — intervention group
Group type: COMPARATOR
Intervention: phenylbutazone
Number of subjects: 20
Study 343727 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 20
Study 31858245 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (Ursodeoxycholic acid)
Number of subjects: 1432
Study 31858245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1432
Study 31858245 — intervention group
Group type: EXPERIMENTAL
Intervention: SG (Sleeve Gastrectomy)
Number of subjects: 1432
Study 31858245 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB (One Anastomosis Gastric Bypass)
Number of subjects: 1432
Study 31858245 — intervention group
Group type: EXPERIMENTAL
Intervention: GCP (Greater Curve Plication)
Number of subjects: 1432
Study 31615796 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-care interventions (various types)
Number of subjects: 1060
Study 28863914 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletally anchored facemasks with miniplates at the zygomatic buttress (Group 1)
Number of subjects: 30
Study 28863914 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III elastics from infrazygomatic miniplates in the maxilla to symphyseal miniplates in the mandible (Group 2)
Number of subjects: 30
Study 28863914 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Group 3)
Number of subjects: 30
Study 26051572 — intervention group
Group type: EXPERIMENTAL
Intervention: PC 6 acupoint stimulation via beaded intervention wristbands
Number of subjects: 80
Study 26051572 — intervention group
Group type: COMPARATOR
Intervention: Placebo sham wristband
Number of subjects: 80
Study 22743782 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients with ST elevation AMI and single vessel disease
Number of subjects: 14
Study 22743782 — intervention group
Group type: COMPARATOR
Intervention: Control group (sinus rhythm patients with AMI and single vessel disease)
Number of subjects: 14
Study 20737495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg/2 mL IV
Number of subjects: 102
Study 20737495 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% 2 mL IV
Number of subjects: 102
Study 19634956 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 0
Study 19634956 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY)
Number of subjects: 0
Study 19634956 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16617930 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 0
Study 15121264 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium (Er):YAG laser
Number of subjects: 42
Study 15121264 — intervention group
Group type: COMPARATOR
Intervention: Surgical bur
Number of subjects: 42
Study 11333173 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (low-dose oral)
Number of subjects: 5
Study 11333173 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 5
Study 11333173 — intervention group
Group type: COMPARATOR
Intervention: Control (Mexiletine)
Number of subjects: 5
Study 9386870 — intervention group
Group type: EXPERIMENTAL
Intervention: Single view mammography screening
Number of subjects: 40318
Study 9386870 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 40318
Study 9386870 — intervention group
Group type: EXPERIMENTAL
Intervention: Single view mammography screening (for women aged 50-64)
Number of subjects: 40318
Study 9386870 — intervention group
Group type: EXPERIMENTAL
Intervention: Single view mammography screening (for women aged 40-49)
Number of subjects: 40318
Study 7952623 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 micrograms)
Number of subjects: 161
Study 7952623 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (180 micrograms)
Number of subjects: 161
Study 7952623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161